Eli Lilly facing civil probe into drug marketing

INDIANAPOLIS: Eli Lilly last week confirmed that it was under investigation by US prosecutors over marketing activities for some of its top-selling drugs.

The Indianapolis-based drugs giant, already being investigated for the way it has promoted its osteoporosis drug Evista, said it believed the new probe would also examine its PR work for top-selling schizophrenia treatment Zyprexa and former blockbuster anti-depressant Prozac.

Lilly confirmed that the US Attorney for the Eastern District of Pennsylvania had kicked off a civil investigation. The company said that an ‘adverse outcome could have a material adverse impact on the company’s consolidated financial position’.

The previously disclosed investigation of Evista by the US Office of Consumer Litigation began in 2002 after a competitor complained that Lilly was improperly marketing the drug as a breast-cancer preventative – a use for which it did not have US Food and Drug Administration approval.

Early last month, Pennsylvania’s state attorney general filed a lawsuit against 13 drugs firms – Lilly was not among them – and accused them of inflating the prices of their products.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Would you like to post a comment?

Please Sign in or register.